-
Je něco špatně v tomto záznamu ?
Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group
A. Janez, E. Muzurovic, AP. Stoian, M. Haluzik, C. Guja, L. Czupryniak, L. Duvnjak, N. Lalic, T. Tankova, P. Bogdanski, N. Papanas, JS. Nunes, P. Kempler, Z. Fras, M. Rizzo
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články
- MeSH
- diabetes mellitus 2. typu * diagnóza farmakoterapie epidemiologie MeSH
- glukagonu podobný peptid 1 metabolismus MeSH
- hypoglykemika farmakologie terapeutické užití MeSH
- kardiovaskulární nemoci * farmakoterapie epidemiologie MeSH
- lidé MeSH
- liraglutid farmakologie terapeutické užití MeSH
- receptor pro glukagonu podobný peptid 1 agonisté MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Glucagon-like peptide-1 (GLP-1) receptor agonists mimic the action of the endogenous GLP-1 incretin hormone, improving glycaemic control in type 2 diabetes mellitus (T2DM) by increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. However, as cardiovascular (CV) morbidity and mortality is common in patients with T2DM, several trials with the use of GLP-1 receptor agonists (RAs) have been performed focusing on endpoints related to cardiovascular disease rather than metabolic control of T2DM. Following the positive cardiovascular effects of liraglutide, dulaglutide and semaglutide observed in these trials, major changes in T2DM management guidelines have occurred. This document from a Eastern and Southern European Diabetes Expert Group discusses the results of GLP-1 RA CV outcomes trials, their impact on recent clinical guidelines for the management of T2DM, and some selected combination regimens utilising GLP-1 RAs. We also propose an algorithm for guiding GLP-1 RA-based treatment according to patients' characteristics, which can be easily applied in every day clinical practice.
1st Department of Medicine Semmelweis University Budapest Hungary
Department of Diabetology and Internal Medicine Medical University of Warsaw Poland
Department of Endocrinology Medical University Sofia Bulgaria
School of Medicine University of Zagreb Vuk Vrhovac University Clinic Zagreb Croatia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22024206
- 003
- CZ-PrNML
- 005
- 20221031100447.0
- 007
- ta
- 008
- 221017s2022 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ijcard.2022.07.017 $2 doi
- 035 __
- $a (PubMed)35905827
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Janez, Andrej $u Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Center Ljubljana, Slovenia. Electronic address: andrej.janez@kclj.si
- 245 10
- $a Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group / $c A. Janez, E. Muzurovic, AP. Stoian, M. Haluzik, C. Guja, L. Czupryniak, L. Duvnjak, N. Lalic, T. Tankova, P. Bogdanski, N. Papanas, JS. Nunes, P. Kempler, Z. Fras, M. Rizzo
- 520 9_
- $a Glucagon-like peptide-1 (GLP-1) receptor agonists mimic the action of the endogenous GLP-1 incretin hormone, improving glycaemic control in type 2 diabetes mellitus (T2DM) by increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. However, as cardiovascular (CV) morbidity and mortality is common in patients with T2DM, several trials with the use of GLP-1 receptor agonists (RAs) have been performed focusing on endpoints related to cardiovascular disease rather than metabolic control of T2DM. Following the positive cardiovascular effects of liraglutide, dulaglutide and semaglutide observed in these trials, major changes in T2DM management guidelines have occurred. This document from a Eastern and Southern European Diabetes Expert Group discusses the results of GLP-1 RA CV outcomes trials, their impact on recent clinical guidelines for the management of T2DM, and some selected combination regimens utilising GLP-1 RAs. We also propose an algorithm for guiding GLP-1 RA-based treatment according to patients' characteristics, which can be easily applied in every day clinical practice.
- 650 12
- $a kardiovaskulární nemoci $x farmakoterapie $x epidemiologie $7 D002318
- 650 12
- $a diabetes mellitus 2. typu $x diagnóza $x farmakoterapie $x epidemiologie $7 D003924
- 650 _2
- $a glukagonu podobný peptid 1 $x metabolismus $7 D052216
- 650 _2
- $a receptor pro glukagonu podobný peptid 1 $x agonisté $7 D000067757
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hypoglykemika $x farmakologie $x terapeutické užití $7 D007004
- 650 _2
- $a liraglutid $x farmakologie $x terapeutické užití $7 D000069450
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Muzurovic, Emir $u Faculty of Medicine, University of Montenegro, Department of Internal Medicine, Endocrinology Section, Clinical Centre of Montenegro, Podgorica, Montenegro
- 700 1_
- $a Stoian, Anca Pantea $u Diabetes, Nutrition and Metabolic Diseases Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
- 700 1_
- $a Haluzik, Martin $u Diabetes Centre and Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine and Institute of Endocrinology, Prague, Czech Republic
- 700 1_
- $a Guja, Cristian $u Department of Diabetes, Nutrition and Metabolic Diseases, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania
- 700 1_
- $a Czupryniak, Leszek $u Department of Diabetology and Internal Medicine, Medical University of Warsaw, Poland
- 700 1_
- $a Duvnjak, Lea $u School of Medicine University of Zagreb, Vuk Vrhovac University Clinic, Zagreb, Croatia
- 700 1_
- $a Lalic, Nebojsa $u Faculty of Medicine University of Belgrade, Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of Serbia, Belgrade, Serbia
- 700 1_
- $a Tankova, Tsvetalina $u Department of Endocrinology, Medical University, Sofia, Bulgaria
- 700 1_
- $a Bogdanski, Pawel $u Department of Treatment of Obesity, Metabolic Disorders and Clinical Dietetics, University of Medical Sciences, Poznan, Poland
- 700 1_
- $a Papanas, Nikolaos $u Diabetes Centre, Second Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece
- 700 1_
- $a Nunes, Josè Silva $u Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário Lisboa Central, Lisbon, Portugal
- 700 1_
- $a Kempler, Peter $u First Department of Medicine, Semmelweis University, Budapest, Hungary
- 700 1_
- $a Fras, Zlatko $u Preventive Cardiology Unit, Division of Medicine, University Medical Centre Ljubljana and Chair of Internal Medicine, Medical Faculty, University of Ljubljana, Slovenia
- 700 1_
- $a Rizzo, Manfredi $u Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (Promise), School of Medicine, University of Palermo, Italy
- 773 0_
- $w MED00002299 $t International journal of cardiology $x 1874-1754 $g Roč. 365, č. - (2022), s. 8-18
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35905827 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20221017 $b ABA008
- 991 __
- $a 20221031100445 $b ABA008
- 999 __
- $a ok $b bmc $g 1854115 $s 1175496
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 365 $c - $d 8-18 $e 20220726 $i 1874-1754 $m International journal of cardiology $n Int J Cardiol $x MED00002299
- LZP __
- $a Pubmed-20221017
